VA
ROIV icon

Vident Advisory’s Roivant Sciences ROIV Stock Holding History

Vident Advisory’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$950K Buy
26,856
+768
+3% +$22.7K 0.01% 989
2026
Q1 		$723K Buy
26,088
+546
+2% +$14K 0.01% 1043
2025
Q4 		$554K Sell
25,542
-54
-0.2% -$1.06K 0.01% 1117
2025
Q3 		$387K Sell
25,596
-696
-3% -$8.62K ﹤0.01% 1295
2025
Q2 		$296K Buy
26,292
+4,856
+23% +$52.6K ﹤0.01% 1309
2025
Q1 		$216K Sell
21,436
-10,603
-33% -$115K ﹤0.01% 1409
2024
Q4 		$379K Buy
32,039
+15,918
+99% +$188K 0.01% 1077
2024
Q3 		$186K Buy
+16,121
New +$184K ﹤0.01% 1332

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Vident Advisory's ROIV Position: Q2 2026 in Review

Vident Advisory increased its Roivant Sciences (ROIV) stake by 2.9% in Q2 2026, buying an estimated $22.7K and bringing the position to 26,856 shares worth $950K. The position accounts for 0.01% of the portfolio, ranked #989.

Vident Advisory first reported a position in ROIV in Q3 2024 and has held it in 8 quarters since. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • Vident Advisory held 26,856 shares of Roivant Sciences worth $950K as of Q2 2026.
  • Vident Advisory bought 768 Roivant Sciences shares in Q2 2026, an estimated $22.7K.
  • Roivant Sciences made up 0.01% of Vident Advisory's portfolio in Q2 2026, its #989 holding.
  • Vident Advisory first reported a position in Roivant Sciences in Q3 2024 and has held it in 8 quarters since.
  • 498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.